Search by Drug Name or NDC
NDC 60505-3252-03 LAMIVUDINE 300 mg/1 Details
LAMIVUDINE 300 mg/1
LAMIVUDINE is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Apotex Corp.. The primary component is LAMIVUDINE.
MedlinePlus Drug Summary
Lamivudine (Epivir) is used along with other medications to treat human immunodeficiency virus (HIV) infection in adults and children 3 months of age and older. Lamivudine (Epivir-HBV) is used to treat hepatitis B infection. Lamivudine is in a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs). It works by decreasing the amount of HIV and hepatitis B in the blood. Although lamivudine does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other lifestyle changes may decrease the risk of transmitting (spreading) the HIV or hepatitis B virus to other people.
Related Packages: 60505-3252-03Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Lamivudine
Product Information
| NDC | 60505-3252 |
|---|---|
| Product ID | 60505-3252_bbf358fa-e61a-1522-02f7-a3e252d4c5e6 |
| Associated GPIs | 12106060000330 |
| GCN Sequence Number | 049905 |
| GCN Sequence Number Description | lamivudine TABLET 300 MG ORAL |
| HIC3 | W5J |
| HIC3 Description | ANTIVIRALS, HIV-SPECIFIC, NUCLEOSIDE ANALOG, RTI |
| GCN | 15709 |
| HICL Sequence Number | 010215 |
| HICL Sequence Number Description | LAMIVUDINE |
| Brand/Generic | Generic |
| Proprietary Name | LAMIVUDINE |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | lamivudine |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 300 |
| Active Ingredient Units | mg/1 |
| Substance Name | LAMIVUDINE |
| Labeler Name | Apotex Corp. |
| Pharmaceutical Class | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Reverse Transcriptase Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA091606 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 60505-3252-03 (60505325203)
| NDC Package Code | 60505-3252-3 |
|---|---|
| Billing NDC | 60505325203 |
| Package | 30 TABLET, FILM COATED in 1 BOTTLE (60505-3252-3) |
| Marketing Start Date | 2011-12-02 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 1.29184 |
| Pricing Unit | EA |
| Effective Date | 2022-02-23 |
| NDC Description | LAMIVUDINE 300 MG TABLET |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 4 |
| Classification for Rate Setting | G |
| As of Date | 2022-11-23 |